Back to DRIEHAUS CAPITAL MANAGEMENT LLC DRIEHAUS CAPITAL MANAGEMENT LLC

SYRESYRE
Showing 8 of 12 quarters

Position history for DRIEHAUS CAPITAL MANAGEMENT LLCDRIEHAUS CAPITAL MANAGEMENT LLC's holdings in SPYRE THERAPEUTICS INC

Yes. Driehaus Capital Management holds 2,799,166 shares of SYRE (Spyre Therapeutics), worth $248.5M, as of its Q2 2026 13F filing. It increased the position by 8,381 shares (+0.3%) from Q1 2026. Driehaus Capital Management has held SYRE since Q3 2023, across 12 quarterly 13F filings. SYRE is 1.4% of Driehaus Capital Management's reported 13F portfolio.

Current Value

$248.5M

Current Shares

2.8M

Total Value Change

+$228.3M

Total Shares Change

+2.1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
2.8M
+0.3%
$248.5M1.4%$88.78
48
2026-Q1
Decreased
2.8M
-3.2%
$140.8M1.0%$50.44
0
2025-Q4
Increased
2.9M
+39.9%
$94.4M0.6%$32.76
56
2025-Q3
Decreased
2.1M
-1.2%
$34.5M0.2%$16.76
0
2025-Q2
Decreased
2.1M
-23.3%
$31.2M0.2%$14.97
0
2025-Q1
Decreased
2.7M
-3.1%
$43.8M0.4%$16.14
0
2024-Q4
Increased
2.8M
+308.1%
$65.3M0.5%$23.28
67
2024-Q3
Unchanged
687,080
0.0%
$20.2M0.2%$29.41
0

Other major holders of SYRE: FMR LLC, BlackRock, Inc., RTW INVESTMENTS, LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used